VASTRA FROLUNDA, Sweden--(BUSINESS WIRE)--The biomaterials company Artimplant (STO:ARTIB) receives regulatory clearance for marketing Artelon® STT Spacer in the USA. The product is indicated for osteoarthritis in the STT joint. Small Bone Innovations, the licensee of Artimplant, now gets the opportunity to market the product at its domestic market USA. Patients in the USA with osteoarthritis in both the CMC and STT joints that previously could not be treated for thumb base osteoarthritis with only Artelon® CMC Spacer will as of now have the possibility to benefit from Artimplant’s Artelon® Spacers in both joints.
